N1 Implant
DeviceThe N1 Implant is a type of implantable brain-computer interface
Other names: Neuralink N1 Implant, N1, Telepathy, Link
NCT Number: NCT06429735
The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.
Interested in participating?
Request Info22 year–75 year
All sexes
Interventional
Not applicable
Barrow Neurological Institute, Phoenix, Arizona, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The N1 Implant is a type of implantable brain-computer interface
Other names: Neuralink N1 Implant, N1, Telepathy, Link
The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
Other names: R1, Neuralink R1 Robot
Time frame: 12 months post-implant
Time frame: 12 months post-implant
Time frame: Up to 72 months post-implant
Time frame: Up to 72 months post-implant
Contact information is provided by the study sponsor or research team.
Neuralink Corp
Industry
PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
Acronym: PRIME
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07224256
Amyotrophic Lateral Sclerosis, Articulation Disorders
Dallas, Texas, United States
View Trial DetailsNCT07127172
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS)
London, Greater London, United Kingdom
View Trial DetailsNCT06992596
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS)
Abu Dhabi, United Arab Emirates
View Trial DetailsNCT06700304
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS)
Toronto, Ontario, Canada
View Trial Details